OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Yonsei Cancer Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Ospedale Policlinico San Martino, The University of Texas Southwestern Medical Center, Emory University, Winship Cancer Institute, Queen Mary University of London, Barts Cancer Institute, Olema Pharmaceuticals (United States), Curtin University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401514884